With the advent of microinvasive glaucoma surgery(MIGS),the spectrum of modalities available to manage patients with this chronic and heterogeneous condition has broadened.Despite its novelty however,there has been a ...With the advent of microinvasive glaucoma surgery(MIGS),the spectrum of modalities available to manage patients with this chronic and heterogeneous condition has broadened.Despite its novelty however,there has been a rapid evolution in the development of a multitude of devices,each targeting a structure along the aqueous drainage pathway.A growing body of evidence has demonstrated IOP and medication burden reduction,and a more favorable safety profile with MIGS procedures in contrast to traditional incisional surgeries.Among the array of MIGS,the Hydrus®Microstent(Ivantis,Inc.,Irvine,CA)is a recent FDA approved device,designed to bypass the trabecular meshwork and provide a scaffold for Schlemm’s canal.The objective of this article is to review the Hydrus from conception to clinical use,and present data on its efficacy and safety to date.The available literature has shown promise,however inherent to all novel devices,only longterm monitoring will ensure sustained IOP control and an acceptable safety profile.Surgical advancements in glaucoma have revolutionized the field,and continued research and development will establish these approaches in clinical treatment algorithms.展开更多
基金support for the research,authorship,and/or publication of this article:this study was supported by Ivantis,Inc.,(Irvine,CA).
文摘With the advent of microinvasive glaucoma surgery(MIGS),the spectrum of modalities available to manage patients with this chronic and heterogeneous condition has broadened.Despite its novelty however,there has been a rapid evolution in the development of a multitude of devices,each targeting a structure along the aqueous drainage pathway.A growing body of evidence has demonstrated IOP and medication burden reduction,and a more favorable safety profile with MIGS procedures in contrast to traditional incisional surgeries.Among the array of MIGS,the Hydrus®Microstent(Ivantis,Inc.,Irvine,CA)is a recent FDA approved device,designed to bypass the trabecular meshwork and provide a scaffold for Schlemm’s canal.The objective of this article is to review the Hydrus from conception to clinical use,and present data on its efficacy and safety to date.The available literature has shown promise,however inherent to all novel devices,only longterm monitoring will ensure sustained IOP control and an acceptable safety profile.Surgical advancements in glaucoma have revolutionized the field,and continued research and development will establish these approaches in clinical treatment algorithms.
